Cisplatinum and prednimustine, an active regimen for advanced epithelial ovarian cancer.
80 patients with advanced epithelial ovarian carcinoma were treated for 6 months with cisplatinum and prednimustine following initial surgery. Response to treatment was assessed by second-look surgery. The objective response rate was 69% with 38% achieving a complete response for up to 55 months. The toxicity of this regimen was acceptable. Statistically, de-bulking or partial de-bulking had a significant beneficial effect on the likelihood of a complete response. The best survival figures were associated with maximum de-bulking. The combination of cisplatinum and prednimustine is a new and active regimen for operable advanced epithelial ovarian carcinoma.
Smyth
J F
JF
University Department of Clinical Oncology, Western General Hospital, Edinburgh, UK.
Beattie
G J
GJ
Stewart
M E
ME
Cowie
V J
VJ
Smart
G E
GE
Livingstone
J R
JR
Leonard
R C
RC
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy*; D002945:Cisplatin / Q000008:administration & dosage; D004341:Drug Evaluation; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D011238:Prednimustine / Q000008:administration & dosage
D011238:Prednimustine; D002945:Cisplatin